Figures computed from official regulatory filings — .
Analysttarget 15.4 USD (+164%) · consensus 4.75/5 · 12 buy · 0 hold · 0 sell
Ownershipinsiders 4.08% · institutions 80.23% · short 11.3% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Shattuck Labs, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
22 buys82 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Shukla Abhinav A. | Exercise | $43.4K | SEC |
| Shukla Abhinav A. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shukla Abhinav A. | Exercise | $1.5K | SEC |
| Shukla Abhinav A. | Sell | $2.9K | SEC |
| Shukla Abhinav A. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pandite Arundathy N. | Sell | $210.3K | SEC |
| Shukla Abhinav A. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shukla Abhinav A. | Sell | $707 | SEC |
| Shukla Abhinav A. | Exercise | $357 | SEC |
| Shukla Abhinav A. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shukla Abhinav A. | Sell | $165.4K | SEC |
| Shukla Abhinav A. | Exercise | $83.4K | SEC |
| ORBIMED ADVISORS LLCtrack record | BuyD (derivative) | n/a (No price was disclosed in the filing) | Cluster | SEC |
| Ashiya Monatrack record | BuyD (derivative) | n/a (No price was disclosed in the filing) | Cluster | SEC |
| Ashiya Monatrack record | BuyD (derivative) | n/a (No price was disclosed in the filing) | Cluster | SEC |
| ORBIMED ADVISORS LLCtrack record | BuyD (derivative) | n/a (No price was disclosed in the filing) | Cluster | SEC |
| SIEGALL CLAY Btrack record | Buy | $250K | conv 39 | SEC |
| Ashiya Monatrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| ORBIMED ADVISORS LLCtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Ashiya Monatrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| ORBIMED ADVISORS LLCtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Ashiya Monatrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Ashiya Monatrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| ORBIMED ADVISORS LLCtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| ORBIMED ADVISORS LLCtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |